Efficacy and Safety of LUXTURNA™ (voretigene neparvovec-rzyl) in Patients with RPE65 Mutation-Associated Inherited Retinal Dystrophy

6/19/2018
14:40 - 15:10

Kathleen Reape

Kathy Reape is Head of Clinical R&D at Spark Therapeutics. She received her MD from the University of Pennsylvania and completed her internship and residency at the University of Florida and the University of Medicine and Dentistry of New Jersey. She has more than 18 years of pharmaceutical industry experience in clinical drug development at Wyeth, Teva and Allergan, prior to joining Spark. She has been involved with numerous clinical trials as well as the approvals of more than 2 dozen products including small molecules, biologics, biosimilars, and devices, spanning a wide range of therapeutic areas.

Presentation(s):

Send Email for Kathleen Reape


Assets

Efficacy and Safety of LUXTURNA™ (voretigene neparvovec-rzyl) in Patients with RPE65 Mutation-Associated Inherited Retinal Dystrophy



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Efficacy and Safety of LUXTURNA™ (voretigene neparvovec-rzyl) in Patients with RPE65 Mutation-Associated Inherited Retinal Dystrophy